opioid receptor mu 1
Last updated 6 Sept 2023
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
The OPRM1 gene provides instructions for making a protein called the mu (μ) opioid receptor. Opioid receptors are part of the endogenous opioid system, which is the body's internal system for regulating pain, reward, and addictive behaviors. It consists of opioid substances produced naturally within the body (called endogenous opioids) and their receptors, into which opioids fit like keys into locks. Opioid receptors are found in the nervous system, where they are embedded in the outer membrane of nerve cells (neurons). When opioids attach (bind) to the receptors, the interaction triggers a series of chemical changes within and between neurons that lead to feelings of pleasure and pain relief.
Video picks for GenesVideo library
Normal function
The OPRM1 gene provides instructions for making a protein called the mu (μ) opioid receptor. Opioid receptors are part of the endogenous opioid system, which is the body's internal system for regulating pain, reward, and addictive behaviors. It consists of opioid substances produced naturally within the body (called endogenous opioids) and their receptors, into which opioids fit like keys into locks. Opioid receptors are found in the nervous system, where they are embedded in the outer membrane of nerve cells (neurons). When opioids attach (bind) to the receptors, the interaction triggers a series of chemical changes within and between neurons that lead to feelings of pleasure and pain relief.
The μ opioid receptor was the first opioid receptor to be discovered. It is the primary receptor for endogenous opioids called beta-endorphin and enkephalins, which help regulate the body's response to pain, among other functions. The μ opioid receptor is also the binding site for many opioids introduced from outside the body (called exogenous opioids). These include commonly prescribed pain medications such as oxycodone, fentanyl, buprenorphine, methadone, oxymorphone, hydrocodone, codeine, and morphine, as well as illegal opioid drugs such as heroin.
When endogenous or exogenous opioids bind to the μ opioid receptor, the interaction triggers a cascade of chemical signals in the nervous system. These signals reduce the activity (excitability) of neurons in certain areas of the brain, which leads to pain relief and feelings of pleasure and intense happiness (euphoria). In addition, the chemical signaling ultimately increases the production of a chemical called dopamine. Dopamine is a chemical messenger (neurotransmitter) that helps regulate areas of the brain involved in reward-seeking behaviour, attention, and mood.
Conditions referring to this gene or chromosome
Other names
LMOR
M-OR-1
MOP
MOR
MOR-1
MOR1
mu opiate receptor
mu opioid receptor hMOR-1a
OPRM
Patient picks for Genes

Diet and nutrition
How much meat should we be eating?
Many people are turning vegetarian and vegan for environmental, ethical, and health reasons. However, meat can also be a good source of protein and provides many important vitamins and minerals, including iron. So how much meat should we be eating - or is it better for us to avoid meat entirely?
by Lynn Stephen

Children's health
Mumps
Mumps is an infection caused by a virus. It mainly affects the salivary glands, which are around the face. Sometimes other parts of the body are affected. Mumps normally affects children, but can occur at any age. Mumps is now uncommon in the UK as children are routinely immunised against mumps.
by Dr Philippa Vincent, MRCGP

Bones, joints and muscles
Muscular dystrophy
Muscular dystrophy is an inherited (genetic) disorder causing muscle weakness. There are different types of muscular dystrophy, which vary as to how severe they are, ranging from very mild to severe. The different types also vary as to what age they begin. If muscular dystrophy is suspected, tests can help to make an accurate diagnosis. Other people in the family can also be tested to see if they have a muscular dystrophy gene. Muscular dystrophy cannot be cured but there are various treatments which can help.
by Dr Doug McKechnie, MRCGP

Treatment and medication
Muscle relaxants
Muscle relaxants are medicines that help the muscles to relax, which may also reduce pain and discomfort. Muscle spasms and tightness may also follow long-term injuries to the head or back. Muscle spasm can also occur as part of a more short-term condition or injury, such as low back pain or whiplash.
by Dr Doug McKechnie, MRCGP

Treatment and medication
Is it safe to take opioid painkillers?
Opioids, a class of strong painkillers which includes codeine and tramadol, are commonly prescribed but carry addiction risks. We explore how to take this type of medication safely.
by Ellie Broughton

Bones, joints and muscles
The most likely reasons for your muscle pain
If you're always busy, rushing about and feeling stressed, it's likely to be a recipe to end up with muscle strains. The good news is there are some simple tips to keep you moving.
by Dr Sarah Jarvis
Related patient information and medicines

Patient information leaflet
Painkillers
There are three main types of painkiller: non-steroidal anti-inflammatory drugs (NSAIDS), paracetamol and opioids. Each works in a different way. ... However, it does not help with inflammation. Opioids work by binding to certain receptors (opioid receptors) in the central nervous system, the gut and other parts of the body. This leads to a.

Patient information leaflet
Can I take Morphine and Paracetamol together?
Paracetamol and morphine have different 'mechanisms of action' (the way they work in the body). Paracetamol works mainly in the central nervous system to reduce pain signals, while morphine attaches to specific 'opioid receptors' to block pain. Because they don't interfere with each other's absorption or breakdown in the liver, they can be used.

Patient information leaflet
Can I take Codeine and Morphine together?
Taking codeine and morphine together significantly increases the risk of serious side effects, including extreme sleepiness, dizziness, and dangerous breathing problems. Because both drugs are strong painkillers from the same family (opioids), they 'stack' on top of each other, which can lead to an accidental overdose. Why this happens Both.

Patient information leaflet
Fibromyalgia
The word fibromyalgia means pain (-algia) coming from the muscles (my-) and fibrous tissues (fibro-) such as tendons and ligaments. The risks of many medications outweigh their potential benefits, and opioid medications should be avoided due to the high risk of addiction and lack of long-term effectiveness. This is described in mo... In 2021, the.

Patient information leaflet
Strong painkillers
Opioids are strong painkillers - medicines used to treat severe pain. ... Opioids (sometimes called opiates) are medicines used to treat pain. Sometimes, a patient may feel that an opioid drug would be useful and the doctor might disagree. The National Institute for Health and Clinical Excellence (NICE) published guidance in 2021 which advised.

Patient information leaflet
Mastocytosis and mast cell disorders
Mast cell activation syndrome You may also see mast cell activation syndrome (MCAS) called mast cell activation disorder (MCAD). Medicines - for example, anaesthetic agents, aspirin, antibiotics, opioids and many other medications. Dr Sarah Jarvis , 28th September 2021 Midostaurin for treating advanced systemic mastocytosis The National Institute.
Further reading and references
- opioid receptor mu 1; MedlinePlus, National Library of Medicine.
- Bonenberger M, Plener PL, Groschwitz RC, Gron G, Abler B. Polymorphism in the micro-opioid receptor gene (OPRM1) modulates neural processing of physical pain, social rejection and error processing. Exp Brain Res. 2015 Sep;233(9):2517-26. doi: 10.1007/s00221-015-4322-9. Epub 2015 May 28.
- Crist RC, Berrettini WH. Pharmacogenetics of OPRM1. Pharmacol Biochem Behav. 2014 Aug;123:25-33. doi: 10.1016/j.pbb.2013.10.018. Epub 2013 Nov 5.
- Davis C, Zai C, Levitan RD, Kaplan AS, Carter JC, Reid-Westoby C, Curtis C, Wight K, Kennedy JL. Opiates, overeating and obesity: a psychogenetic analysis. Int J Obes (Lond). 2011 Oct;35(10):1347-54. doi: 10.1038/ijo.2010.276. Epub 2011 Jan 25.
- Garriock HA, Tanowitz M, Kraft JB, Dang VC, Peters EJ, Jenkins GD, Reinalda MS, McGrath PJ, von Zastrow M, Slager SL, Hamilton SP. Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder. Am J Psychiatry. 2010 May;167(5):565-73. doi: 10.1176/appi.ajp.2009.08081167. Epub 2010 Mar 1.
- Haerian BS, Haerian MS. OPRM1 rs1799971 polymorphism and opioid dependence: evidence from a meta-analysis. Pharmacogenomics. 2013 May;14(7):813-24. doi: 10.2217/pgs.13.57.
- Pasternak G, Pan YX. Mu opioid receptors in pain management. Acta Anaesthesiol Taiwan. 2011 Mar;49(1):21-5. doi: 10.1016/j.aat.2010.12.008. Epub 2011 Mar 17.
- Pasternak GW, Pan YX. Mu opioids and their receptors: evolution of a concept. Pharmacol Rev. 2013 Sep 27;65(4):1257-317. doi: 10.1124/pr.112.007138. Print 2013.
- Reed B, Butelman ER, Yuferov V, Randesi M, Kreek MJ. Genetics of opiate addiction. Curr Psychiatry Rep. 2014 Nov;16(11):504. doi: 10.1007/s11920-014-0504-6.
- Schwantes-An TH, Zhang J, Chen LS, Hartz SM, Culverhouse RC, Chen X, Coon H, Frank J, Kamens HM, Konte B, Kovanen L, Latvala A, Legrand LN, Maher BS, Melroy WE, Nelson EC, Reid MW, Robinson JD, Shen PH, Yang BZ, Andrews JA, Aveyard P, Beltcheva O, Brown SA, Cannon DS, Cichon S, Corley RP, Dahmen N, Degenhardt L, Foroud T, Gaebel W, Giegling I, Glatt SJ, Grucza RA, Hardin J, Hartmann AM, Heath AC, Herms S, Hodgkinson CA, Hoffmann P, Hops H, Huizinga D, Ising M, Johnson EO, Johnstone E, Kaneva RP, Kendler KS, Kiefer F, Kranzler HR, Krauter KS, Levran O, Lucae S, Lynskey MT, Maier W, Mann K, Martin NG, Mattheisen M, Montgomery GW, Muller-Myhsok B, Murphy MF, Neale MC, Nikolov MA, Nishita D, Nothen MM, Nurnberger J, Partonen T, Pergadia ML, Reynolds M, Ridinger M, Rose RJ, Rouvinen-Lagerstrom N, Scherbaum N, Schmal C, Soyka M, Stallings MC, Steffens M, Treutlein J, Tsuang M, Wall TL, Wodarz N, Yuferov V, Zill P, Bergen AW, Chen J, Cinciripini PM, Edenberg HJ, Ehringer MA, Ferrell RE, Gelernter J, Goldman D, Hewitt JK, Hopfer CJ, Iacono WG, Kaprio J, Kreek MJ, Kremensky IM, Madden PA, McGue M, Munafo MR, Philibert RA, Rietschel M, Roy A, Rujescu D, Saarikoski ST, Swan GE, Todorov AA, Vanyukov MM, Weiss RB, Bierut LJ, Saccone NL. Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts. Behav Genet. 2016 Mar;46(2):151-69. doi: 10.1007/s10519-015-9737-3. Epub 2015 Sep 21.
- Walter C, Doehring A, Oertel BG, Lotsch J. micro-opioid receptor gene variant OPRM1 118 A>G: a summary of its molecular and clinical consequences for pain. Pharmacogenomics. 2013 Nov;14(15):1915-25. doi: 10.2217/pgs.13.187.
- Xu J, Lu Z, Xu M, Pan L, Deng Y, Xie X, Liu H, Ding S, Hurd YL, Pasternak GW, Klein RJ, Cartegni L, Zhou W, Pan YX. A heroin addiction severity-associated intronic single nucleotide polymorphism modulates alternative pre-mRNA splicing of the mu opioid receptor gene OPRM1 via hnRNPH interactions. J Neurosci. 2014 Aug 13;34(33):11048-66. doi: 10.1523/JNEUROSCI.3986-13.2014.
Share your thoughts or experiences with others in our patient communities.
Sign up to the Patient newsletter
Your weekly dose of clear, trustworthy health advice - written to help you feel informed, confident and in control.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.

